Nilotinib Stada

Nilotinib, the active ingredient in Nilotinib Stada, is a tyrosine kinase inhibitor presented as an oral formulation for systemic use. It is indicated for the treatment of chronic myeloid leukemia and related BCR‑ABL positive disorders in adult patients.

GNH USA supplies Nilotinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib targets the BCR‑ABL driven pathway that underlies chronic myeloid leukemia and related hematologic malignancies. - Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and improves hematologic response. - Chronic myeloid leukemia (accelerated phase): helps achieve cytogenetic and molecular remission. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (in combination therapy): contributes to disease control and prolongs survival.

Common side effects are generally mild to moderate and may affect treatment tolerability.

Common Side Effects: - Nausea: occasional upset stomach or vomiting. - Diarrhea: loose stools that may require fluid replacement. - Rash: mild skin irritation or erythema. - Fatigue: feeling unusually tired or weak.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias and requires ECG monitoring. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Pancreatitis: abdominal pain with elevated pancreatic enzymes.

Nilotinib requires careful monitoring and patient education to minimize risks. - Cardiac monitoring: obtain baseline ECG and periodically assess QT interval. - Hepatic function: check liver enzymes before initiation and during therapy. - Electrolyte balance: correct hypokalemia and hypomagnesemia to reduce QT risk. - Drug interactions: avoid concomitant strong CYP3A4 inhibitors and QT‑prolonging agents. - Store at room temperature: keep in the original container, protect from moisture and light.

Nilotinib has several clinically relevant drug interactions that may alter its exposure or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase nilotinib levels and risk of toxicity. - QT‑prolonging agents (e.g., macrolide antibiotics, fluoroquinolones): additive cardiac risk. - Antacids or supplements that raise gastric pH: markedly reduce nilotinib absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib exposure and reduce efficacy. - Warfarin: nilotinib can affect INR; monitor coagulation parameters regularly.